Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy

Combination of interferon alfa-2b and ribavirin in relapsed or nonresponding chronic hepatitis C patients following interferon therapy

Twenty six patients (pts) with chronic hepatitis C (CHC) who reLapsed or non-responded following.interferon (IFN) therapy were given lFN alfa-2b 3 MIU three times a week for 48 weeks in combination with Ribavirin 800-1000 mg daily 2I (80,8%) of the 26.pts completed the study consisted of 12 relap...

Full description

Bibliographic Details
Main Authors:	Laurentius A. Lesmana, Unggul Budihusodo, Nurul Akbar, Ali Sulaiman, Sjaifoellah Noer, Inge A. Kristanti, Rianto Setiabudy
Format:	Article
Language:	English
Published:	Faculty of Medicine Universitas Indonesia 2001-11-01
Series:	Medical Journal of Indonesia
Online Access:	http://mji.ui.ac.id/journal/index.php/mji/article/view/37

Similar Items

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

High Dose Consensus Interferon in Nonresponders to Interferon Alpha-2B and Ribavirin with Chronic Hepatitis C
by: David N Moskovitz, et al.
Published: (2003-01-01)

Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?
by: Giovanni Faria Silva, et al.

Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01)

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin
by: M.H.P. Pavan, et al.

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01)

Ribavirin plus interferon alfa in the treatment of chronic hepatitis C infection
by: Wen Hwang Chen, et al.
Published: (2000)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
by: R. Rodríguez-Lojo, et al.
Published: (2010-01-01)

Autoantibodies profile in patients with chronic hepatitis C and the influence of Interferon-alfa plus Ribavirin
by: Janaina LeitÃo Vilar
Published: (2006)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015-07-01)

Treatment of Ribavirin/Pegylated Interferon Alfa - Induced Anemiawith Erythropoietin in Patients with Chronic Hepatitis C
by: Li-Shuan Chen, et al.
Published: (2006)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review
by: J Shepherd, et al.
Published: (2000-12-01)

Pityriasis Rosea Associated with Pegylated Interferon Alfa and Ribavirin Treatment in a Patient with Chronic Hepatitis C
by: Rahmet Güner, et al.
Published: (2013-06-01)

Tratamiento de la crioglobulinemia asociada al virus de la hepatitis C (VHC) con interferón alfa + ribavirina Treatment for hepatitis C virus associated cryoglobulinemia with interferon alfa and ribavirin
by: L. Altuna, et al.
Published: (2005-07-01)

Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
by: Jaber Al Ali, et al.
Published: (2010-04-01)

Response factors to pegylated interferon-alfa/ribavirin treatment in chronic hepatitis C patients genotype 1b
by: Jovanović-Ćupić Snežana, et al.
Published: (2014-01-01)

Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina
by: F. Carnicer, et al.
Published: (2005-05-01)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)

Comparison study between the treatment of Hepatitis C virus with (peg-interferon, ribavirin, silymarin) and (peg-interferon, ribavirin) in Baghdad teaching hospital.
by: Khalid A. Al-Khazraji
Published: (2017-04-01)

Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with Pegylated interferon alfa-2a and ribavirin
by: Fabri Milotka, et al.
Published: (2013-01-01)

Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy
by: Al-Qahtani Ahmed, et al.
Published: (2010-01-01)

The Association of Liver Fibrosis with Effectiveness of Pegylated Interferon Alfa-2b Plus Ribavirin for Chronic Hepatitis C
by: Yi-chih Chen, et al.
Published: (2007)

Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C Recombinant Interferon alfa-2b plus Ribavirin in treatment of chronic hepatitis C
by: Yoan Antonio Sánchez Rodríguez, et al.
Published: (2010-06-01)

The role of splanchnic vasoconstrictor in decreasing peripheral vasodilatation to reduce ascites formation of liver cirrhosis
by: Nurul Akbar, et al.
Published: (1997-10-01)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
by: Saleem Sana, et al.
Published: (2011-05-01)

TREATMENTS OF HEPATITIS C VIRUS LIVER CIRRHOSIS WITH PEGYLAT INTERFERON-RIBAVIRIN AND INTERFERON FREE – COMPARATIVE STUDY
by: S.A. Florescu, et al.
Published: (2016-12-01)

Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis
by: Ming-Chao Tsai, et al.
Published: (2009-09-01)

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
by: J Shepherd, et al.
Published: (2007-03-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Association of SNPs In Interferon Receptor Genes in Chronic Hepatitis C with Response to Combined Therapy of Interferon and Ribavirin
by: Zohreh Heidari, et al.
Published: (2014-10-01)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)

Efficacy and Safety of Ribavirin plus High Dose Interferonα-2b for Treatment of Patients with Chronic Hepatitis C Who Relapsed After Previous Interferon-α Therapy
by: Hsin-Yi Wang, et al.
Published: (2001)

Standard Interferon and Ribavirin Response in Patients with Chronic Hepatitis C
by: Muhammad Murtaza Bukhari
Published: (2013-12-01)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)

Efficacy of Combination Sofosbuvir, Pegylated-Interferon, and Ribavirin for Treatment of Hepatitis C Virus Genotype 1 Infection in Indonesia
by: Andri Sanityoso Sulaiman, et al.
Published: (2018-08-01)

A Multicenter Study To Evaluate The Safety And Efficacy Of Heber On (Interferon Alfa-2b) In Combination With Ribavirin For The Treatment Of Chronic Hepatitis C In Iran
by: H. Mirmomen, et al.
Published: (2005-05-01)

Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
by: Ružić Maja, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_q3ccgbmcg3mm2spq2fdljrdnjp